

Certificate of Analysis for NR-43192

Monoclonal Anti-Rift Valley Fever Virus Gc Glycoprotein, Clone 5E2 (produced in vitro)

Catalog No. NR-43192

This reagent is the property of the U.S. Government.

Product Description: Mouse monoclonal antibody prepared against the Rift Valley fever virus (RVFV) Gc glycoprotein was purified from clone 5E2 hybridoma supernatant by protein G affinity chromatography.

Lot: 61892546 Manufacturing Date: 27SEP2013

TEST	SPECIFICATIONS	RESULTS
Antibody Class Determination	IgG1ĸ	IgG1κ
Experion Pro260 Analysis	Correct molecular weight (MW) for heavy and light chains Report results	Correct MW for heavy and light chains 98.9% pure
Concentration by Spectrophotometer at OD ₂₈₀	Report results	1.5 mg per mL
Functional Activity ¹ Indirect immunofluorescence assay (IFA) titer ² Plaque reduction neutralization test (PRNT) titers PRNT ₅₀ ³ PRNT ₈₀ ⁴	Report results Report results Report results	256000 160 ≤ 20
Sterility	0.22 µm filter-sterilized	0.22 µm filter-sterilized

¹Testing performed at U.S. Army Medical Research Institute of Infectious Diseases

Date: 22 JAN 2015

Signature:

Title: Technical Manager, BEI Authentication or designee

Michael Q. Comple

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

²The IFA titer is defined as the reciprocal of the lowest antibody dilution where glycoprotein staining was clearly visible above background in RVFV MP12-infected Vero E6 cells.

³The PRNT₅₀ is defined as the reciprocal of the antibody dilution required to reduce the number of RVFV ZH501 plaques in Vero E6 cells by 50% relative to the control wells.

³The PRNT₈₀ is defined as the reciprocal of the antibody dilution required to reduce the number of RVFV ZH501 plaques in Vero E6 cells by 80% relative to the control wells.